Rituximab Therapy for Primary Sjögren’s Syndrome
Primary Sjögren’s syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A cardinal pathogenetic feature of SS is B-cell hyperactivity, which has invited efforts on optimal B-cell targeted therapy,...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.731122/full |
| _version_ | 1818729367903141888 |
|---|---|
| author | Yi Han Chen Xin Yu Wang Xin Jin Zi Yang Jianguang Xu |
| author_facet | Yi Han Chen Xin Yu Wang Xin Jin Zi Yang Jianguang Xu |
| author_sort | Yi Han Chen |
| collection | DOAJ |
| description | Primary Sjögren’s syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A cardinal pathogenetic feature of SS is B-cell hyperactivity, which has invited efforts on optimal B-cell targeted therapy, whereas conventional corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are restricted to symptomatic relief. As per the first EULAR recommendation for pSS patients published in 2020, regimens with monoclonal antibodies targeting B cells may be initiated in patients with severe, refractory systemic disease, notably rituximab (RTX), a mouse-derived monoclonal antibody that targets CD20 antigen and contributes to B-cell depletion. Nonetheless, the data available from clinical trials with RTX are often controversial. Despite the lack of promising results from two large RCTs, several positive clinical efficacies were demonstrated. This current review addressed the efficacy and safety of clinical trials available and elucidated the potential of RTX on the immune system, especially B and T cells. Furthermore, plausible explanations for the discrepancy in clinical data were also presented. |
| first_indexed | 2024-12-17T22:44:46Z |
| format | Article |
| id | doaj.art-d7c2d09be8c5451ebc55a4e367a30dd8 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-17T22:44:46Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-d7c2d09be8c5451ebc55a4e367a30dd82022-12-21T21:29:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-09-011210.3389/fphar.2021.731122731122Rituximab Therapy for Primary Sjögren’s SyndromeYi Han ChenXin Yu WangXin JinZi YangJianguang XuPrimary Sjögren’s syndrome (pSS) is a systemic autoimmune diseases of the connective tissues, characteristic of the presentation of keratoconjunctivitis sicca and xerostomia. A cardinal pathogenetic feature of SS is B-cell hyperactivity, which has invited efforts on optimal B-cell targeted therapy, whereas conventional corticosteroids and disease-modifying antirheumatic drugs (DMARDs) are restricted to symptomatic relief. As per the first EULAR recommendation for pSS patients published in 2020, regimens with monoclonal antibodies targeting B cells may be initiated in patients with severe, refractory systemic disease, notably rituximab (RTX), a mouse-derived monoclonal antibody that targets CD20 antigen and contributes to B-cell depletion. Nonetheless, the data available from clinical trials with RTX are often controversial. Despite the lack of promising results from two large RCTs, several positive clinical efficacies were demonstrated. This current review addressed the efficacy and safety of clinical trials available and elucidated the potential of RTX on the immune system, especially B and T cells. Furthermore, plausible explanations for the discrepancy in clinical data were also presented.https://www.frontiersin.org/articles/10.3389/fphar.2021.731122/fullrituximabprimary Sjögren’s syndromeB-cell depletionanti-CD20 therapyB cell repopulation |
| spellingShingle | Yi Han Chen Xin Yu Wang Xin Jin Zi Yang Jianguang Xu Rituximab Therapy for Primary Sjögren’s Syndrome Frontiers in Pharmacology rituximab primary Sjögren’s syndrome B-cell depletion anti-CD20 therapy B cell repopulation |
| title | Rituximab Therapy for Primary Sjögren’s Syndrome |
| title_full | Rituximab Therapy for Primary Sjögren’s Syndrome |
| title_fullStr | Rituximab Therapy for Primary Sjögren’s Syndrome |
| title_full_unstemmed | Rituximab Therapy for Primary Sjögren’s Syndrome |
| title_short | Rituximab Therapy for Primary Sjögren’s Syndrome |
| title_sort | rituximab therapy for primary sjogren s syndrome |
| topic | rituximab primary Sjögren’s syndrome B-cell depletion anti-CD20 therapy B cell repopulation |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.731122/full |
| work_keys_str_mv | AT yihanchen rituximabtherapyforprimarysjogrenssyndrome AT xinyuwang rituximabtherapyforprimarysjogrenssyndrome AT xinjin rituximabtherapyforprimarysjogrenssyndrome AT ziyang rituximabtherapyforprimarysjogrenssyndrome AT jianguangxu rituximabtherapyforprimarysjogrenssyndrome |